RAC 1.11% $1.83 race oncology ltd

Coformulation would be Zan + Carfilzomib in one single drug. We...

  1. 2,664 Posts.
    lightbulb Created with Sketch. 3252
    Coformulation would be Zan + Carfilzomib in one single drug. We don't have that patent, nor do we have that product.

    RAC has submitted synergy patents (not coformulation) for at least 15 different drug synergies (I might have missed some).

    https://hotcopper.com.au/data/attachments/6241/6241721-82faf8b8b57c2eb6369ecf73958c4f52.jpg

    Note that this announcement is the progression (cell - > mouse) of the work announced in 2021.

    https://raceoncology.com/expanded-heart-protection-discovery-for-zantrene/

    What's interesting is statements like these:

    https://hotcopper.com.au/data/attachments/6241/6241734-7f856b6cb5e091d8a0fc5d904892320c.jpg

    Strongly implies an update to Doan et al that was published in February re Zan's impact on HCM viability, broadly.

    https://www.sciencedirect.com/science/article/pii/S144395062400043X

 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.83
Change
0.020(1.11%)
Mkt cap ! $310.7M
Open High Low Value Volume
$1.81 $1.83 $1.79 $142.0K 78.77K

Buyers (Bids)

No. Vol. Price($)
1 500 $1.81
 

Sellers (Offers)

Price($) Vol. No.
$1.83 641 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.